- Home
- CNTA
as 03-25-2025 12:31pm EST
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
| Founded: | 2020 | Country: | United Kingdom |
| Employees: | N/A | City: | ALTRINCHAM, CHESHIRE |
| Market Cap: | 2.2B | IPO Year: | 2021 |
| Target Price: | $23.17 | AVG Volume (30 days): | 994.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.75 - $19.09 | Next Earning Date: | 03-24-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Centessa Pharmaceuticals plc (CNTA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SAHA SAURABH | CNTA | Chief Executive Officer | Mar 20 '25 | Sell | $16.69 | 55,000 | $918,060.00 | 276,017 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | Mar 17 '25 | Sell | $16.45 | 6,000 | $98,697.00 | 105,386 | |
| CHAO DAVID M | CNTA | Chief Administrative Officer | Mar 17 '25 | Sell | $17.29 | 7,000 | $120,205.87 | 225,007 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Feb 25 '25 | Sell | $15.25 | 11,494 | $175,269.71 | 134,021 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Feb 20 '25 | Sell | $16.23 | 55,000 | $876,087.94 | 276,017 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | Feb 18 '25 | Sell | $16.48 | 6,000 | $97,065.44 | 105,386 | |
| Anderson Karen M. | CNTA | Chief People Officer | Feb 7 '25 | Sell | $19.01 | 30,955 | $588,943.54 | 54,322 | |
| Bush Tia L | CNTA | Chief Technology & Quality Ofc | Feb 1 '25 | Sell | $16.86 | 11,000 | $185,406.10 | 121,503 | |
| Anderson Karen M. | CNTA | Chief People Officer | Feb 1 '25 | Sell | $16.86 | 6,471 | $109,124.36 | 54,322 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Jan 27 '25 | Sell | $16.47 | 11,742 | $193,429.49 | 134,021 |
Latest Centessa Pharmaceuticals plc News
CNTA Breaking Stock News: Dive into CNTA Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
GlobeNewswire
19 days ago
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
MT Newswires
a month ago
Centessa Pharmaceuticals Insider Sold Shares Worth $588,944, According to a Recent SEC Filing
GlobeNewswire
2 months ago
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Insider Monkey
2 months ago
Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20?
Insider Monkey
3 months ago
Is Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25?
GlobeNewswire
3 months ago
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
MT Newswires
3 months ago
TD Cowen Initiates Centessa Pharmaceuticals ADR at Buy
Compare CNTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTA Centessa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.